Clinical Significance
Retatrutide represents a significant advancement in obesity pharmacotherapy as the first triple agonist medication, simultaneously activating GLP-1, GIP, and glucagon receptors.[1] In Phase 2 clinical trials, participants receiving the highest dose (12mg) achieved an average weight loss of 24.2% at 48 weeks—the highest weight reduction observed in obesity trials to date.[1] Remarkably, 83% of participants on this dose achieved at least 15% weight loss, a threshold associated with substantial improvements in obesity-related health conditions.[1]
The success of Phase 2 has led to the TRIUMPH Phase 3 program, a comprehensive evaluation across five clinical trials examining retatrutide's effects on obesity, type 2 diabetes, cardiovascular disease, obstructive sleep apnea, and knee osteoarthritis.[3,4] With FDA filing expected in late 2025 and potential approval in 2026, retatrutide could become the most effective weight loss medication available.[5]
What Research Questions Are Being Answered?
The TRIUMPH program investigates retatrutide's potential across multiple obesity-related conditions
Can triple agonism surpass dual agonism for chronic weight management?
Can retatrutide reduce cardiovascular events in obesity?
Can weight loss with retatrutide treat obstructive sleep apnea?
Can retatrutide reduce knee pain in obesity-related osteoarthritis?
Development Timeline
Retatrutide's development from early research through Phase 3 trials and FDA submission
Proof of Concept
- 24.2% weight loss (12mg dose) at 48 weeks vs 2.1% placebo
- 100% achieved ≥5% weight loss at 8mg and 12mg doses
- 83% achieved ≥15% weight loss at 12mg dose
- N=338 participants
Pivotal Phase 2 trial demonstrating unprecedented weight loss efficacy, exceeding tirzepatide (22.5%) and semaglutide (14.9%). Established dose-dependent efficacy with 12mg as optimal dose.
Results justified comprehensive TRIUMPH Phase 3 program. Published in NEJM June 2023, providing scientific foundation for regulatory submission expected in 2025.
- BMI ≥30 kg/m² or ≥27 kg/m² with comorbidity
- Age 18-65 years
- Stable weight for 3 months prior
- Willing to adhere to lifestyle modifications
- Type 2 diabetes
- Prior GLP-1 agonist use
- Recent bariatric surgery
- Significant cardiovascular disease
Phase 2 trial evaluated four dose levels against placebo, revealing clear dose-dependent weight loss:[1]
Mean Weight Loss at 48 Weeks
- Retatrutide 1mg: −8.7% weight loss
- Retatrutide 4mg: −17.1% weight loss
- Retatrutide 8mg: −22.8% weight loss
- Retatrutide 12mg: −24.2% weight loss (58 pounds absolute)
- Placebo: −2.1% weight loss
Dose Escalation: Gradual titration over 20-24 weeks improved GI tolerability while achieving target dose.
Responder rate analyses show percentage of participants achieving clinically meaningful weight loss thresholds:[1]
12mg Dose (Optimal):
- ≥5% weight loss: 100% of participants
- ≥10% weight loss: 93% of participants
- ≥15% weight loss: 83% of participants
The 15% weight loss threshold is clinically important for type 2 diabetes remission and cardiovascular risk reduction. That 83% achieved this threshold demonstrates broad efficacy across diverse populations.
Phase 2 trial demonstrated that retatrutide achieves unprecedented weight loss (24.2%) in adults with obesity—exceeding tirzepatide (22.5%) and semaglutide (14.9%) from their pivotal trials. The triple agonist mechanism (GIP/GLP-1/glucagon) appears to provide additive metabolic benefits beyond dual agonism. The 12mg dose showed optimal efficacy-safety balance, with GI side effects manageable through gradual dose escalation. These results provided compelling evidence to advance retatrutide to Phase 3 TRIUMPH program.
Phase 3 Clinical Program
The TRIUMPH program includes five Phase 3 trials, each designed to answer specific clinical questions about retatrutide's efficacy and safety across different patient populations.
- BMI ≥30 kg/m² or ≥27 kg/m² with comorbidity
- Adults 18+ years
- Willingness to maintain lifestyle modifications
TRIUMPH-1 is the pivotal registration trial providing primary efficacy and safety data for FDA approval. Success in this trial is essential for retatrutide to gain approval for obesity treatment.
- Type 2 diabetes with A1C 7-10%
- BMI ≥27 kg/m²
- On stable diabetes medications
If successful, TRIUMPH-2 could support dual indication approval for both obesity and type 2 diabetes, similar to tirzepatide's Mounjaro (diabetes) and Zepbound (obesity) approvals.
- Obesity (BMI ≥27)
- Prior myocardial infarction, stroke, or peripheral artery disease
- Cardiovascular stability for trial participation
Critical safety trial in high-risk CV population. If retatrutide demonstrates CV benefits (like semaglutide in SELECT), it could support cardiovascular risk reduction indication.
- BMI ≥27
- Symptomatic knee osteoarthritis
- Pain impacting daily activities
Unique trial targeting osteoarthritis symptoms. Success could establish retatrutide as first weight-loss medication labeled for OA symptom management, potentially delaying or avoiding knee replacement surgery.
- Obesity
- Elevated cardiovascular risk
- Willingness for long-term follow-up (3-5 years)
Long-term CVOT mirroring SELECT trial design. If successful, could support cardiovascular risk reduction and chronic kidney disease indications—differentiating retatrutide from weight-loss-only medications.
Safety & Tolerability
Common Adverse Events
Based on Phase 2 data and ongoing Phase 3 safety monitoring, the most common adverse events with retatrutide are gastrointestinal:[1]
Gastrointestinal Events:
- Nausea: Most common adverse event, occurring in 14-60% of participants (dose-dependent), primarily during dose escalation. Most cases were mild to moderate and resolved over time.
- Vomiting: Occurred in 3-26% of participants compared to 1% with placebo. Vomiting led to treatment discontinuation in 1-3% of participants.
- Diarrhea: Dose-dependent, primarily during the titration phase, with mild to moderate severity.
- Constipation: Reported, though specific frequency not provided. Constipation is typical of incretin-based therapies.
These gastrointestinal events are mechanism-based effects—they occur because GLP-1 receptor activation slows gastric emptying (stomach emptying), which contributes to both weight loss (increased satiety) and GI side effects.
Discontinuation Rates
In Phase 2, 6-16% of participants discontinued retatrutide due to adverse events (primarily GI), compared to 0% discontinuation in the placebo group.[1] The discontinuation rate was dose-dependent, with higher rates at higher doses.
For context, discontinuation rates for GI side effects are similar across incretin-based therapies: approximately 4-7% for semaglutide and 4-6% for tirzepatide in their respective obesity trials.
Dose Escalation Strategy
To improve tolerability, the TRIUMPH Phase 3 trials employ a gradual dose escalation strategy:[3,4]
- Lower starting dose: Begin at 2mg rather than 4mg
- Gradual titration: Slowly increase dose over several weeks
- Individualized dosing: Allow participants to remain at a lower dose if higher doses are not tolerated
- Clinical monitoring: Regular check-ins during the dose escalation period to manage side effects
Phase 2 data showed that starting at 2mg (instead of 4mg) partially mitigated GI events, validating this approach.[1]
Safety Profile Comparison
Retatrutide's safety profile is consistent with the class effects of incretin-based therapies (GLP-1 agonists and dual GLP-1/GIP agonists).[1] Gastrointestinal events are expected mechanism-based effects seen with all medications in this class. The overall tolerability of retatrutide appears comparable to approved therapies like semaglutide and tirzepatide, with most adverse events being mild to moderate and transient.
Secondary Benefits Observed
Beyond weight loss, Phase 2 participants experienced improvements in multiple cardiometabolic risk factors:[1]
- Blood Pressure: Reductions in both systolic and diastolic blood pressure
- Lipids: Improvements in triglycerides and cholesterol levels
- Glucose Markers: Reductions in A1C, even in participants without diabetes
- Liver Function: Potential benefits for non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH), though this requires further study
These secondary benefits suggest that retatrutide may improve overall metabolic health beyond weight reduction alone.
Long-term Safety Monitoring
The TRIUMPH Phase 3 program includes comprehensive long-term safety monitoring:[3,4,6]
- Extended safety follow-up periods (up to 113 weeks in TRIUMPH-3)
- Cardiovascular safety monitoring (TRIUMPH-3 and TRIUMPH-Outcomes)
- Kidney function monitoring (TRIUMPH-Outcomes)
- Surveillance for rare adverse events typical of GLP-1-based therapies:
- Pancreatitis (inflammation of the pancreas)
- Gallbladder disease (gallstones)
- Thyroid events (medullary thyroid carcinoma—black box warning for GLP-1 agonists)
These long-term safety assessments are critical for regulatory approval and post-market surveillance.
Frequently Asked Questions
Retatrutide is in Phase 3 clinical development. The TRIUMPH program includes five active Phase 3 trials evaluating obesity (TRIUMPH-1), type 2 diabetes with obesity (TRIUMPH-2), cardiovascular disease (TRIUMPH-3), knee osteoarthritis (TRIUMPH-4), and cardiovascular/kidney outcomes (TRIUMPH-Outcomes). Phase 2 trials were completed in 2023.
TRIUMPH trial results are expected throughout 2024-2025. Eli Lilly has indicated that FDA filing is expected in late 2025, which suggests that primary endpoint data from TRIUMPH-1 and TRIUMPH-2 will be available by mid-2025.[5] The cardiovascular outcomes trial (TRIUMPH-Outcomes) will take longer, typically 3-5 years, with results likely in 2027-2028.
In Phase 2, retatrutide's 12mg dose demonstrated 24.2% weight loss at 48 weeks.[1] By comparison, tirzepatide (Zepbound) showed approximately 21% weight loss at 72 weeks in the SURMOUNT-1 trial. However, these are different trials with different patient populations, durations, and study designs. Head-to-head trials comparing retatrutide and tirzepatide have not been conducted, so direct superiority cannot be established. Both medications are manufactured by Eli Lilly.
Yes, several TRIUMPH trials are actively recruiting participants:
- TRIUMPH-1: Adults with obesity or overweight
- TRIUMPH-2: Adults with type 2 diabetes and obesity
- TRIUMPH-4: Adults with obesity and knee osteoarthritis
- TRIUMPH-Outcomes: Adults with obesity and cardiovascular risk factors
Eligibility criteria vary by trial but generally include adults with BMI ≥30 (obesity) or BMI ≥27 with weight-related comorbidities (overweight). Visit ClinicalTrials.gov and search for the NCT identifiers listed in this article to find trial locations near you and review detailed eligibility criteria.
Retatrutide is the first triple agonist, simultaneously activating GLP-1, GIP, and glucagon receptors.[1] Currently approved therapies are either:
- Single agonists: Semaglutide (Wegovy) activates only GLP-1 receptors
- Dual agonists: Tirzepatide (Zepbound) activates GLP-1 and GIP receptors
The addition of glucagon receptor activation may explain retatrutide's higher weight loss in Phase 2 trials. Glucagon increases energy expenditure and promotes fat burning, complementing the appetite-suppressing effects of GLP-1 and the metabolic benefits of GIP.
FDA approval is expected in 2026 based on Eli Lilly's projected late 2025 filing.[5] The standard FDA review period for a New Drug Application (NDA) is 10-12 months. However, approval timing depends on:
- Successful completion of TRIUMPH Phase 3 trials
- Positive efficacy and safety data
- FDA review process (potential for priority review if granted)
- Resolution of any regulatory questions or requests for additional data
It's important to note that this is a projection, not a confirmed timeline. Clinical trials can encounter delays, and FDA review timelines can vary.
The most common side effects are gastrointestinal:[1]
- Nausea (14-60%, dose-dependent)
- Vomiting (3-26%)
- Diarrhea
- Constipation
These side effects are primarily mild to moderate and occur mostly during dose escalation. About 6-16% of participants in Phase 2 discontinued treatment due to GI side effects. Gradual dose escalation and starting at a lower dose can help improve tolerability.
Yes. The TRIUMPH program includes trials evaluating retatrutide for:
- Type 2 diabetes with obesity (TRIUMPH-2)
- Cardiovascular disease (TRIUMPH-3)
- Knee osteoarthritis (TRIUMPH-4)
- Cardiovascular and kidney outcomes (TRIUMPH-Outcomes)
This broad clinical program could lead to multiple FDA-approved indications, positioning retatrutide as a versatile medication for obesity and related conditions.
Retatrutide is administered as a subcutaneous injection (under the skin) once weekly, similar to Wegovy and Zepbound.[1,2] The injection is self-administered using a pre-filled pen device. Weekly dosing improves convenience compared to daily medications.
Phase 2 data showed higher weight loss with retatrutide (24.2%) compared to approved medications (Wegovy ~15%, Zepbound ~21%).[1] However, Phase 3 TRIUMPH trials must confirm these results in larger, more diverse populations before superiority can be established.
Additionally, FDA approval does not automatically grant superiority claims. To make such claims, head-to-head trials directly comparing retatrutide to Wegovy or Zepbound would be required. As of now, these head-to-head trials have not been announced.
References
- Jastreboff AM, Kaplan LM, Frías JP, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. doi:10.1056/NEJMoa2301972https://www.nejm.org/doi/full/10.1056/NEJMoa2301972
- Phase 2 Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight. ClinicalTrials.gov Identifier: NCT04881760. Updated December 2023.https://clinicaltrials.gov/study/NCT04881760
- A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight (TRIUMPH-1). ClinicalTrials.gov Identifier: NCT05929066.https://clinicaltrials.gov/study/NCT05929066
- A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes and Obesity or Overweight (TRIUMPH-2). ClinicalTrials.gov Identifier: NCT05929079.https://clinicaltrials.gov/study/NCT05929079
- Eli Lilly and Company. Lilly's phase 2 retatrutide results published in The New England Journal of Medicine [Press Release]. June 26, 2023.https://investor.lilly.com/news-releases/news-release-details/lillys-phase-2-retatrutide-results-published-new-england-journal
- A Study of Retatrutide (LY3437943) to Assess Cardiovascular Outcomes and Kidney Outcomes in Participants Living With Obesity (TRIUMPH-Outcomes). ClinicalTrials.gov Identifier: NCT06383390.https://clinicaltrials.gov/study/NCT06383390
Last updated November 28, 2025